IgA NephropathyNews & Research
16 curated articles for IgA Nephropathy — FDA updates, peer-reviewed research, clinical-trial milestones, and sponsor press releases. Sorted newest-first.
- Kidney international Apr 18, 2026
Evidence from multicenter clinical studies and humanized mouse models indicates that glomerular mesangial IgA2 deposition contributes to the pathogenesis of IgA nephropathy.
While IgA1 is well established as pathogenic in IgA nephropathy (IgAN), IgA2's role remains controversial. The most notable difference between IgA1 and IgA2 lies in the hinge region: IgA2 lacks a 13-amino acid segment unique in IgA1, which contains nine serine and threonine residues that can be O-gl...
Why it matters: Recent peer-reviewed research on IgA Nephropathy that may be relevant for patients and caregivers.
- BMC Nephrol Mar 28, 2026
The UK Eastern Network for Kidney Inflammatory Disease (ENKID) MDT at 24 months: advancing access to high-cost drugs, clinical trials, and complex case management in renal autoimmune diseases
Published in BMC Nephrol. Francis L et al.
Why it matters: Recent peer-reviewed research relevant to rare disease diagnosis or treatment.
- Frontiers in immunology Mar 25, 2026
Autoimmunity in IgA nephropathy.
IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. Its pathogenesis is widely described by a multi-hit hypothesis in which galactose-deficient IgA1 (Gd-IgA1) serves as a central disease driver. Advances in the understanding of IgAN pathophysiology, together with the esta...
Why it matters: Recent peer-reviewed research on IgA Nephropathy that may be relevant for patients and caregivers.
- Kidney international Mar 21, 2026
Multi-omics analyses reveal the pathogenic role of terminal ileum-derived IgA + β7 + cells in IgA nephropathy.
Galactose-deficient IgA1 (Gd-IgA1) plays a key role in IgA nephropathy (IgAN), but the location of the plasma cells responsible for its production remain unknown. To locate Gd-IgA1-producing cells, we profiled intestinal and circulating immune cells from three independent cohorts totaling 99 IgAN ca...
Why it matters: Recent peer-reviewed research on IgA Nephropathy that may be relevant for patients and caregivers.
- Journal of clinical medicine Mar 14, 2026
IgA Nephropathy: Epidemiology, Outcomes, and Insights for Primary Glomerulonephritides.
According to the Global Burden of Disease 2019 analysis, there were 606,300 new cases of chronic kidney disease due to glomerulonephritis worldwide, with 17.3 million prevalent cases and 183,700 deaths More interestingly, between 1990 and 2019, the global burden of glomerulonephritis increased by 77...
Why it matters: Recent peer-reviewed research on IgA Nephropathy that may be relevant for patients and caregivers.
- JAMA Mar 6, 2026
IgA Nephropathy in Adults: A Review.
IgA nephropathy (IgAN) is a chronic kidney disease involving deposition of IgA-containing immune complexes in the glomerulus, causing glomerular inflammation and scarring. It is the most common immune-mediated glomerular disease worldwide, and affects an estimated 198 887 to 208 184 pe...
Why it matters: Recent peer-reviewed research on IgA Nephropathy that may be relevant for patients and caregivers.
- BMC nephrology Mar 5, 2026
Efficacy of semaglutide in IgA nephropathy with obesity: a case report.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) like semaglutide are well-used for type 2 diabetes and obesity, and recent studies show their potential renal benefits in both diabetic and non-diabetic people. However, evidence for semaglutide’s efficacy in IgAN especially in patients wi...
Why it matters: Recent peer-reviewed research on IgA Nephropathy that may be relevant for patients and caregivers.
- Kidney360 Mar 4, 2026
Nephron Number and Kidney Outcomes in IgA Nephropathy: A Retrospective Cohort Study.
No previous studies have examined the clinical significance of nephron number in patients with IgA nephropathy. In patients with IgA nephropathy, a lower number of nephrons per kidney was significantly associated with an increased rate of subsequent decline in kidney function. These findings highlig...
Why it matters: Recent peer-reviewed research on IgA Nephropathy that may be relevant for patients and caregivers.
- Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association Feb 23, 2026
Disease modification in immunoglobulin A nephropathy.
With the rapidly expanding therapeutic landscape in IgA nephropathy, that incorporates new drugs with varied mechanisms of action, many of which may lead to modification of the fundamental pathophysiology of the world's commonest glomerular disease, thoughts are now turning to how we should define d...
Why it matters: Recent peer-reviewed research on IgA Nephropathy that may be relevant for patients and caregivers.
- Frontiers in immunology Feb 23, 2026
Efficacy and safety of Nefecon in IgA nephropathy: real world clinical practice.
The targeted-release budesonide formulation (Nefecon) addresses IgA nephropathy (IgAN) by inhibiting mucosal immune dysregulation in gut-associated lymphoid tissue (GALT), leading to reduced production of galactose-deficient IgA1 (Gd-IgA1). Randomized controlled trials (NEFIGAN, NefIgArd) have shown...
Why it matters: Recent peer-reviewed research on IgA Nephropathy that may be relevant for patients and caregivers.
- Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association Feb 23, 2026
How should we target and reduce the production of pathogenic IgA in IgAN?
IgA nephropathy represents the most common primary glomerulonephritis worldwide and is characterized by a progressive decline in kidney function, with a large proportion of patients developing kidney failure within their lifetime. Significant progress in the understanding of its pathogenesis has led...
Why it matters: Recent peer-reviewed research on IgA Nephropathy that may be relevant for patients and caregivers.
- The New England journal of medicine Feb 11, 2026
Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial.
The cytokine A proliferation-inducing ligand (APRIL) is considered a key driver of the pathogenesis of IgA nephropathy. Sibeprenlimab, a humanized IgG2 monoclonal antibody, selectively binds to and inhibits APRIL. In this phase 3, multicenter, double-blind, randomized, placebo-controlled trial, we a...
Why it matters: Recent peer-reviewed research on IgA Nephropathy that may be relevant for patients and caregivers.
- The New England journal of medicine Feb 11, 2026
A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy.
IgA nephropathy, the most common primary glomerulopathy worldwide, is a kidney disorder of B-cell origin characterized by mesangial accumulation of IgA-containing immune complexes. In at least 50% of patients, IgA nephropathy leads to kidney failure or death within 10 to 20 years after diagnosis. At...
Why it matters: Recent peer-reviewed research on IgA Nephropathy that may be relevant for patients and caregivers.
- Clinical and experimental nephrology Feb 9, 2026
Initial proteinuria reduction and adverse kidney outcomes in IgA nephropathy: an analysis from the J-IGACS.
Proteinuria reduction is considered a potential surrogate endpoint predictive of reflecting long-term kidney prognosis in IgA nephropathy (IgAN), but quantitative evidence in Japanese patients is limited. We aimed to examine the association between short-term proteinuria reduction at 12 months ...
Why it matters: Recent peer-reviewed research on IgA Nephropathy that may be relevant for patients and caregivers.
- Pediatric nephrology (Berlin, Germany) Jan 28, 2026
Prognosis and predictive factors in pediatric IgA nephropathy.
IgA nephropathy (IgAN) is a common glomerular disease in children that may progress to chronic kidney disease (CKD) and kidney failure. Identifying reliable prognostic markers is important for guiding clinical management. This study investigated independent predictors of poor prognosis in pediatric ...
Why it matters: Recent peer-reviewed research on IgA Nephropathy that may be relevant for patients and caregivers.
- BreakingFDA Sep 15, 2025
Filspari Approved for IgA Nephropathy
The FDA approved Filspari (sparsentan), a dual endothelin and angiotensin receptor antagonist, for IgA nephropathy at risk of disease progression.
Why it matters: First disease-modifying therapy specifically for IgA Nephropathy. Landmark for rare kidney diseases.
More on IgA Nephropathy
Articles aggregated from peer-reviewed journals (PubMed), sponsor press releases, SEC 8-K filings, and FDA announcements. Original-source links are preserved on each article page. Editorial tags (Breaking / Notable / Update) reflect UniteRare's curation-time priority assessment.